Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
100 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2016', provides an overview of the Chemotherapy Induced Nausea and Vomiting pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting - The report reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Chemotherapy Induced Nausea and Vomiting therapeutics and enlists all their major and minor projects - The report assesses Chemotherapy Induced Nausea and Vomiting therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Chemotherapy Induced Nausea and Vomiting Overview 9 Therapeutics Development 10 Pipeline Products for Chemotherapy Induced Nausea and Vomiting - Overview 10 Chemotherapy Induced Nausea and Vomiting - Therapeutics under Development by Companies 11 Chemotherapy Induced Nausea and Vomiting - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Chemotherapy Induced Nausea and Vomiting - Products under Development by Companies 17 Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development 19 Acacia Pharma Limited 19 Aphios Corporation 20 Astellas Pharma Inc. 21 Athenex, Inc. 22 Helsinn Healthcare S.A. 23 Heron Therapeutics, Inc. 24 INSYS Therapeutics, Inc. 25 Kyowa Hakko Kirin Co., Ltd. 26 Merck & Co., Inc. 27 RedHill Biopharma Ltd. 28 SoluBest Ltd. 29 Suda Ltd 30 Tesaro, Inc. 31 Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Combination Products 33 Assessment by Target 34 Assessment by Mechanism of Action 36 Assessment by Route of Administration 38 Assessment by Molecule Type 40 Drug Profiles 41 (netupitant + palonosetron hydrochloride) - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 (palonosetron hydrochloride + Pro-netupitant) - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 APD-403 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 aprepitant - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 aprepitant - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 aprepitant - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 dronabinol - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 dronabinol - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 FK-886 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 fosaprepitant dimeglumine - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 granisetron - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 granisetron ER - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 granisetron ER - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 granisetron hydrochloride - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 LPI-1504 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 LPI-1505 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 NB-1222 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 netupitant - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 ondansetron hydrochloride - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 ondansetron hydrochloride - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 ondansetron hydrochloride - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 ondansetron hydrochloride CR - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 rolapitant hydrochloride - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Chemotherapy Induced Nausea and Vomiting - Recent Pipeline Updates 72 Chemotherapy Induced Nausea and Vomiting - Dormant Projects 89 Chemotherapy Induced Nausea and Vomiting - Discontinued Products 91 Chemotherapy Induced Nausea and Vomiting - Product Development Milestones 92 Featured News & Press Releases 92 Feb 04, 2016: FDA Approves Merck's Single-Dose EMEND (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy 92 Feb 01, 2016: Biologics Announces New Oncology Partnership 93 Jan 15, 2016: Heron Therapeutics Notified by FDA That It Will Not Take Action on SUSTOL New Drug Application by the PDUFA Date 93 Dec 15, 2015: Swissmedic Approves Akynzeo (netupitant/palonosetron) for use in the Prevention of Chemotherapy Induced Nausea and Vomiting in Switzerland 93 Nov 16, 2015: OPKO Licensee TESARO Announces the Launch of VARUBI (Rolapitant) in the United States 94 Nov 13, 2015: Helsinn Group and Eisai Announce Inclusion of AKYNZEO in American Society of Clinical Oncology Antiemetics Guid 94 Oct 14, 2015: Helsinn's AKYNZEO (netupitant/palonosetron) nominated within the category "Best Pharmaceutical Agent of the Year" at The Galien Foundation Prix Award 95 Sep 28, 2015: Heron Therapeutics Announces Oral Presentation of Data from Completed Phase 3 MAGIC Study for SUSTOL at the ASCO Breast Cancer Symposium 96 Sep 24, 2015: TESARO Announces Inclusion of VARUBI (rolapitant) in NCCN Antiemesis Guidelines 97 Sep 22, 2015: Heron Therapeutics to Present Data From Completed Phase 3 MAGIC Study of SUSTOL at ASCO Breast Cancer Symposium 98 Appendix 99 Methodology 99 Coverage 99 Secondary Research 99 Primary Research 99 Expert Panel Validation 99 Contact Us 99 Disclaimer 100
List of Tables
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2016 10 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Comparative Analysis by Unknown Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Development by Companies, H1 2016 (Contd..1) 18 Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Limited, H1 2016 19 Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corporation, H1 2016 20 Chemotherapy Induced Nausea and Vomiting - Pipeline by Astellas Pharma Inc., H1 2016 21 Chemotherapy Induced Nausea and Vomiting - Pipeline by Athenex, Inc., H1 2016 22 Chemotherapy Induced Nausea and Vomiting - Pipeline by Helsinn Healthcare S.A., H1 2016 23 Chemotherapy Induced Nausea and Vomiting - Pipeline by Heron Therapeutics, Inc., H1 2016 24 Chemotherapy Induced Nausea and Vomiting - Pipeline by INSYS Therapeutics, Inc., H1 2016 25 Chemotherapy Induced Nausea and Vomiting - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 26 Chemotherapy Induced Nausea and Vomiting - Pipeline by Merck & Co., Inc., H1 2016 27 Chemotherapy Induced Nausea and Vomiting - Pipeline by RedHill Biopharma Ltd., H1 2016 28 Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd., H1 2016 29 Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Ltd, H1 2016 30 Chemotherapy Induced Nausea and Vomiting - Pipeline by Tesaro, Inc., H1 2016 31 Assessment by Monotherapy Products, H1 2016 32 Assessment by Combination Products, H1 2016 33 Number of Products by Stage and Target, H1 2016 35 Number of Products by Stage and Mechanism of Action, H1 2016 37 Number of Products by Stage and Route of Administration, H1 2016 39 Number of Products by Stage and Molecule Type, H1 2016 40 Chemotherapy Induced Nausea and Vomiting Therapeutics - Recent Pipeline Updates, H1 2016 72 Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H1 2016 89 Chemotherapy Induced Nausea and Vomiting - Dormant Projects (Contd..1), H1 2016 90 Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H1 2016 91
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.